1. Home
  2. MAIA vs FMST Comparison

MAIA vs FMST Comparison

Compare MAIA & FMST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • FMST
  • Stock Information
  • Founded
  • MAIA 2018
  • FMST 2005
  • Country
  • MAIA United States
  • FMST Canada
  • Employees
  • MAIA N/A
  • FMST 2
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • FMST Other Metals and Minerals
  • Sector
  • MAIA Health Care
  • FMST Basic Materials
  • Exchange
  • MAIA Nasdaq
  • FMST Nasdaq
  • Market Cap
  • MAIA 46.7M
  • FMST 45.1M
  • IPO Year
  • MAIA 2022
  • FMST N/A
  • Fundamental
  • Price
  • MAIA $1.85
  • FMST $3.26
  • Analyst Decision
  • MAIA
  • FMST
  • Analyst Count
  • MAIA 0
  • FMST 0
  • Target Price
  • MAIA N/A
  • FMST N/A
  • AVG Volume (30 Days)
  • MAIA 543.2K
  • FMST 909.4K
  • Earning Date
  • MAIA 08-08-2025
  • FMST 01-01-0001
  • Dividend Yield
  • MAIA N/A
  • FMST N/A
  • EPS Growth
  • MAIA N/A
  • FMST N/A
  • EPS
  • MAIA N/A
  • FMST N/A
  • Revenue
  • MAIA N/A
  • FMST N/A
  • Revenue This Year
  • MAIA N/A
  • FMST N/A
  • Revenue Next Year
  • MAIA N/A
  • FMST N/A
  • P/E Ratio
  • MAIA N/A
  • FMST N/A
  • Revenue Growth
  • MAIA N/A
  • FMST N/A
  • 52 Week Low
  • MAIA $1.40
  • FMST $0.55
  • 52 Week High
  • MAIA $4.24
  • FMST $5.74
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 53.36
  • FMST 49.42
  • Support Level
  • MAIA $1.82
  • FMST $2.89
  • Resistance Level
  • MAIA $2.03
  • FMST $3.95
  • Average True Range (ATR)
  • MAIA 0.12
  • FMST 0.37
  • MACD
  • MAIA 0.02
  • FMST -0.13
  • Stochastic Oscillator
  • MAIA 58.14
  • FMST 34.91

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About FMST Foremost Lithium Resource & Technology Ltd. Common stock

Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec. Geographically it covers Canada and United states.

Share on Social Networks: